Payment overview · 2025
General Payments
$647.31
26 reported records · 11 companies
Healthcare provider profile · identity verified
Barry Groves, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GREENVILLE, KY · NPI 1508259862
Verified facts
What the public records show
CMS Open Payments records show Barry Groves, APRN received $647.31 in general payments during 2025 across 26 reported records.
Amgen Inc. accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $258.55 | 39.9% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.70 | 21.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $76.04 | 11.8% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.95 | 4.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.78 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.48 | 4.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.03 | 3.7% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $19.56 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.19 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.17 | 2.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.86 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $647.31 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $145.53 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.45 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $76.04 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.91 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.11 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.11 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.95 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.48 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.48 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $27.89 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 277 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 264 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 234 | 44 |
| Lisinopril | Lisinopril | 221 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 29 |
| Metformin Hcl | Metformin Hcl | 154 | 34 |
| Omeprazole | Omeprazole | 139 | 29 |
| Losartan Potassium | Losartan Potassium | 125 | 23 |
| Sertraline Hcl | Sertraline Hcl | 119 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 21 |
| Valsartan | Valsartan | 107 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 26 |
| Metformin Hcl Er | Metformin Hcl | 93 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 21 |
| Gabapentin | Gabapentin | 92 | 16 |
| Buspirone Hcl | Buspirone Hcl | 90 | 20 |
| Furosemide | Furosemide | 86 | 18 |
| Ezetimibe | Ezetimibe | 85 | 16 |
| Famotidine | Famotidine | 73 | 13 |
| Potassium Chloride | Potassium Chloride | 70 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 20 |
| Glipizide | Glipizide | 68 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | suppressed |
| Lovastatin | Lovastatin | 65 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 14 |
| Montelukast Sodium | Montelukast Sodium | 63 | 15 |
| Carvedilol | Carvedilol | 61 | 16 |
| Eliquis | Apixaban | 58 | 14 |
| Meloxicam | Meloxicam | 58 | suppressed |
| Simvastatin | Simvastatin | 57 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 52 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 52 | 14 |
| Ozempic | Semaglutide | 51 | 13 |
| Allopurinol | Allopurinol | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | 11 |
| Prednisone | Prednisone | 41 | 35 |
| Fenofibrate | Fenofibrate,micronized | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | suppressed |
| Nystatin | Nystatin | 36 | 14 |
| Sucralfate | Sucralfate | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 19 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Atrovent Hfa | Ipratropium Bromide | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | 11 |
| Clonazepam | Clonazepam | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $647.31 · 26 records | Amgen Inc. | Auvelity, EVENITY, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, PROLIA, REPATHA, TAVNEOS, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error